"The US Food and Drug Administration (FDA) has approved a quarterly injection form of paliperidone (Invega Trinza, Janssen Pharmaceuticals) for schizophrenia, the company announced today.
Janssen Pharmaceuticals already markets a "...
Discuss the following issues with patients and caregivers:
- Severe Neutropenia:
- Instruct patients (and caregivers) beginning treatment with FAZACLO about the risk of developing severe neutropenia and infection.
- Instruct patients to immediately report to their physician any symptom or sign of infection (e.g., flu-like illness; fever; lethargy; general weakness or malaise; mucus membrane ulceration; skin, pharyngeal, vaginal, urinary, or pulmonary infection; or extreme weakness or lethargy) occurring at any time during FAZACLO therapy, to aid in evaluation for neutropenia and to institute prompt and appropriate management. [see WARNINGS AND PRECAUTIONS].
- Inform patients and caregivers FAZACLO is available only
through a restricted program called the Clozapine REMS Program designed to
ensure the required blood monitoring, in order to reduce the risk of developing
severe neutropenia. Advise patients and caregivers of the importance of having
blood tested as follows:
- Weekly blood tests are required for the first 6 months.
- An ANC is required every 2 weeks for the next 6 months if an acceptable ANC is maintained during the first 6 months of continuous therapy.
- An ANC is required once every 4 weeks thereafter if an acceptable ANC is maintained during the second 6 months of continuous therapy.
- FAZACLO is available only from certified pharmacies participating in the program. Provide patients (and caregivers) with website information and the telephone number on how to obtain the product.
- Orthostatic Hypotension, Bradycardia, and Syncope: Inform patients and caregivers about the risk of orthostatic hypotension and syncope, especially during the period of initial dose titration. Instruct them to strictly follow the clinician's instructions for dosage and administration. Advise patients to consult their clinician immediately if they feel faint, lose consciousness or have signs or symptoms suggestive of bradycardia or arrhythmia [see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS].
- Seizures: Inform patients and caregivers about the significant risk of seizure during FAZACLO treatment. Caution them about driving and any other potentially hazardous activity while taking FAZACLO [see WARNINGS AND PRECAUTIONS].
- QT Interval Prolongation: Advise patients to consult their clinician immediately if they feel faint, lose consciousness, or have signs or symptoms suggestive of arrhythmia. Instruct patients to not take FAZACLO with other drugs that cause QT interval prolongation. Instruct patients to inform their clinicians that they are taking FAZACLO before any new drug [see WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS].
- Metabolic Changes (hyperglycemia and diabetes mellitus, dyslipidemia, weight gain): Educate patients and caregivers about the risk of metabolic changes and the need for specific monitoring. The risks include hyperglycemia and diabetes mellitus, dyslipidemia, weight gain, and cardiovascular reactions. Educate patients and caregivers about the symptoms of hyperglycemia (high blood sugar) and diabetes mellitus (e.g., polydipsia, polyuria, polyphagia, and weakness). Monitor all patients for these symptoms. Patients who are diagnosed with diabetes or have risk factors for diabetes (obesity, family history of diabetes) should have their fasting blood glucose monitored before beginning treatment and periodically during treatment. Patients who develop symptoms of hyperglycemia should have assessments of fasting glucose. Clinical monitoring of weight is recommended [see WARNINGS AND PRECAUTIONS].
- Patients with Phenylketonuria: Inform patients and caregivers that FAZACLO contains phenylalanine (a component of aspartame) [see WARNINGS AND PRECAUTIONS].
- Interference with Cognitive and Motor Performance: Because FAZACLO may have the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that FAZACLO therapy does not affect them adversely [see WARNINGS AND PRECAUTIONS].
- Missed Doses and Re-Initiating Treatment: Inform patients and caregivers that if the patient misses taking FAZACLO for more than 2 days, he or she should not restart his or her medication at the same dosage but should contact their physician for dosing instructions [see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS].
- Pregnancy: Patients and caregivers should notify the clinician if the patient becomes pregnant or intends to become pregnant during therapy [see Use In Specific Populations].
- Nursing: Advise patients and caregivers that the patient should not breast feed an infant if she is taking FAZACLO [see Use in Specific Populations].
- Concomitant Medication: Advise patients to inform their health care provider if they are taking, or plan to take, any prescription or over-the-counter drugs; there is a potential for significant drug-drug interactions [see DOSAGE AND ADMINISTRATION, DRUG INTERACTIONS, and Table 1].
- Administration: Patients should be advised that FAZACLO tablets should remain in the original package until immediately before use [see DOSAGE AND ADMINISTRATION].
Last reviewed on RxList: 10/1/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Fazaclo Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on therapy and treatment.